Valvular & structural heart disease
Initial Experience with Transcatheter Tricuspid Valve Repair in Patients with Cardiac Amyloidosis
Authors' conclusion
Transcatheter tricuspid valve repair is a safe and feasible new treatment option in patients with amyloid cardiomyopathy and has the potential to improve TR-grade and clinical status. However, the benefit appears to be less pronounced compared with patients without cardiac amyloidosis.
Study context
- Population
- Patients with severe to torrential tricuspid regurgitation (TR) undergoing successful transcatheter tricuspid valve repair
- Participants
- 8 vs 21
- Exposure
- Transcatheter tricuspid valve repair in ATTRwt amyloidosis vs patients without cardiac amyloidosis
- Amyloidosisn = 8
- Controln = 21reference
- Outcome
- Reduction in TR
- Follow-up
- 3 months
Main finding
As reported in the abstract
TR reduction
| Group | Value | TR grade | TR-reduction |
|---|---|---|---|
| Amyloidosis | 100% | IV to II, P = 0.008 | 1.6 ± 0.3, P = 0.008 |
| Control | 2.3 ± 0.3, P < 0.0001 |
Value
Amyloidosis100%
Control— not stated in the abstract
TR grade
AmyloidosisIV to II, P = 0.008
Control— not stated in the abstract
TR-reduction
Amyloidosis1.6 ± 0.3, P = 0.008
Control2.3 ± 0.3, P < 0.0001
Observational data: associations, not effects.
Secondary outcomes
Device success · 3 months
P = 0.597
Hospitalization or death · 3 months
P = 0.646
NYHA class and 6-min walk distance (amyloidosis)
- Improvement in NYHA class
- P = 0.031
- 6-min walk distance from 313 ± 118 to 337 ± 106
- P = 0.012
Structural right heart parameters (amyloidosis)
- No significant improvement
Original publication
Initial Experience with Transcatheter Tricuspid Valve Repair in Patients with Cardiac Amyloidosis. ESC Heart Fail. Published 13 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →